Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Sardesai Niranjan
 2. Date of Event Requiring Statement (Month/Day/Year)
01/03/2012		 3. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [INO]
(Last)
(First)
(Middle)
11494 SORRENTO VALLEY ROAD, SUITE A		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Operating Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SAN DIEGO, CA 92121		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 66,800
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Option (1) 08/28/2006 08/28/2016 Common Stock 132,462 $ 1.53 D  
Common Stock Option (1) 01/05/2007 01/05/2017 Common Stock 24,530 $ 1.53 D  
Common Stock Option (1) 01/18/2007 01/18/2017 Common Stock 14,718 $ 1.53 D  
Common Stock Option (1) 11/01/2007 11/01/2017 Common Stock 73,590 $ 1.53 D  
Common Stock Option (1) 09/12/2008 09/12/2018 Common Stock 29,436 $ 1.53 D  
Common Stock Option (1) 09/12/2008 09/12/2018 Common Stock 19,624 $ 1.53 D  
Common Stock Option (2) 09/30/2009 09/30/2019 Common Stock 120,000 $ 1.57 D  
Common Stock Option (3) 03/11/2011 03/11/2021 Common Stock 120,000 $ 1.14 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Sardesai Niranjan
11494 SORRENTO VALLEY ROAD
SUITE A
SAN DIEGO, CA 92121		       Chief Operating Officer  

Signatures

/s/ Niranjan Sardesai 01/04/2012
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Issued upon assumption of outstanding VGX Pharmaceutical Inc. stock options in conjunction with closing of the business combination transaction between VGX Pharmaceuticals and Inovio Pharmaceuticals, Inc. on June 1, 2009. As of January 4, 2012, options are fully vested and exercisable.
(2) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on September 30, 2009; 30,000 shares vested on September 30, 2010; 30,000 shares vested on September 30, 2011; 30,000 shares will vest on September 30, 2012.
(3) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on March 11, 2011; 30,000 shares will vest on March 11, 2012; 30,000 shares will vest on March 11, 2013; 30,000 shares will vest on March 11, 2014

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.